NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis $1.56 -0.08 (-4.60%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Voyager Therapeutics Stock (NASDAQ:VYGR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Voyager Therapeutics alerts:Sign Up Key Stats Today's Range$1.55▼$1.6750-Day Range$1.63▼$3.4052-Week Range$1.55▼$5.48Volume557,181 shsAverage Volume674,854 shsMarket Capitalization$96.77 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingModerate Buy Company Overview Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs. Founded in 2014, Voyager is based in Lexington, Massachusetts. Its research and development activities focus on genetic medicine technologies and potential treatments for patients with serious neurological conditions.AI Generated. May Contain Errors. Read More Voyager Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreVYGR MarketRank™: 2.394356868455 of 5 starsVoyager Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 537th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialVoyager Therapeutics has a consensus price target of $25.00, representing about 1,476.3% upside from its current price of $1.59.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Voyager Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.60) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.06% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 20.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.03 News SentimentVoyager Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Voyager Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.70% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYGR Stock News HeadlinesVoyager Therapeutics (NASDAQ:VYGR) Downgraded by Wall Street Zen to Strong SellNovember 7, 2026 | americanbankingnews.comVoyager Reports Third Quarter 2026 Financial and Operating ResultsNovember 6, 2026 | markets.businessinsider.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 17 at 1:00 AM | Behind the Markets (Ad)Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026October 27, 2026 | markets.businessinsider.comVoyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026October 27, 2026 | globenewswire.comVoyager Therapeutics (VYGR) Gets a Buy from Wells FargoOctober 24, 2026 | theglobeandmail.comVoyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock DownOctober 22, 2026 | rttnews.comVoyager Announces CEO Succession Plan, Appoints Robin Swartz PresidentOctober 21, 2026 | globenewswire.comSee More Headlines VYGR Stock Analysis - Frequently Asked Questions How have VYGR shares performed this year? Voyager Therapeutics' stock was trading at $3.93 on January 1st, 2026. Since then, VYGR shares have decreased by 59.6% and is now trading at $1.5860. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. The business had revenue of $612 thousand for the quarter, compared to analysts' expectations of $6.35 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 63.42% and a negative net margin of 416.32%. When did Voyager Therapeutics IPO? Voyager Therapeutics (VYGR) raised $80 million in an initial public offering on Wednesday, November 11th 2015. The company issued 5,000,000 shares at $15.00-$17.00 per share. Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' top institutional investors include State Street Corp (1.76%), Goldman Sachs Group Inc. (0.92%), Marshall Wace LLP (0.35%) and Empowered Funds LLC (0.12%). Insiders that own company stock include Alfred Sandrock, Robin Swartz, Nathan D Jorgensen, Todd Alfred Carter and Sandell Jacquelyn Fahey. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX) and Palantir Technologies (PLTR). Company Calendar Last Earnings11/05/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VYGR's financial health is in the Red zone, according to TradeSmith. VYGR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VYGR CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees141Year Founded2014Price Target and Rating Average Price Target for Voyager Therapeutics$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+1,507.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.72 million Net Margins-416.32% Pretax Margin-416.08% Return on Equity-63.42% Return on Assets-49.40% Debt Debt-to-Equity RatioN/A Current Ratio6.81 Quick Ratio7.51 Sales & Book Value Annual Sales$40.37 million Price / Sales2.40 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book0.72Miscellaneous Outstanding Shares62,230,000Free Float54,326,000Market Cap$96.77 million OptionableOptionable Beta1.20 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:VYGR) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.